Results 231 to 240 of about 208,148 (266)

New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia

Asian Pacific Journal of Cancer Prevention, 2017
Background: Polymorphic bases in several exons of the BCR gene have been found in several studies of the BCR-ABL fusion gene. Most of the polymorphisms do not have any implications for the primary structure of the BCR-ABL protein.
Tri Agusti Sholikah, S. H. Hutajulu, Dewi Sulistyawati, Sumartiningsih Aning, S. Fatmawati, Anditta Syifarahmah, K. Widayati, J. Kurnianda, D. K. Paramita   +8 more
semanticscholar   +1 more source

A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..

Blood, 2008
Abstract Specific tyrosine kinase inhibition (TKI) of the bcr-abl fusion protein in Philadelphia chromosome positive chronic myelogenous leukemia (CML) was introduced into general use in 2000 after a plenary abstract presentation to ASH in December 1999.
Anmmd Kamruzzaman, Nanette Cox-Kennett, Loree Larratt, Deborah A. Rusnak, Joanne D. Hewitt, A. Robert Turner, Andrew Belch   +6 more
openaire   +2 more sources

Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)

Journal of Clinical Oncology, 2006
6591 Background: AMN107 is a novel, highly selective oral Bcr-Abl inhibitor which is 20–50-fold more potent than imatinib. High response rates with AMN107 were observed in all CML phases post imatinib failure. Methods: Study Aims: Evaluate the efficacy of AMN107in newly diagnosed Ph-positive CML-CP.
G. Garcia-Manero, A. Salvado, S. O'Brien, Francis J. Giles, Laurie Letvak, E. Jabbour, J. E. Cortes, Hagop M. Kantarjian, G. Borthakur, Farhad Ravandi   +9 more
openaire   +2 more sources

Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous Leukemia (CML-CP).

Blood, 2006
Nilotinib is a novel, highly selective oral Bcr-Abl inhibitor which is approximately 30-fold more potent than imatinib. High response rates with nilotinib were observed in all CML phases post imatinib failure. We evaluated the efficacy of nilotinib in newly diagnosed Ph-positive CML-CP.
Laurie Letvak, Laurie Letvak, Elias Jabbour, Hagop M. Kantarjian, Susan O'Brien, Jorge E. Cortes, Francis J. Giles   +6 more
openaire   +2 more sources

Patterns of Clonal Evolution in Ph’-Positive Chronic Myelogenous Leukemia (CML) during Chronic Phase: Overall Incidence, Type, Multiplicity, Development Time, Effect on Subsequent Genetic Instability, Sokal Risk, Type of bcr/abl Transcript and Hematological Evolution.

Blood, 2006
Abstract Fifty-two kariotypic abnormalities additional to Philadelphia chromosome (Ph’) were documented at the time of diagnosis or during the course of the disease in 114 CML patients. Five were evaluated only once at the time of diagnosis, while 109 were repeatedly studied overtime during a median period of 138 (1–275)months.
Luzi D, Falchi L, Emili R, Angeletti I, Prontera P, Venti G, Bassetti A, Gubbiotti M, Capparella V, Gentileschi E, Donti E, LIBERATI, Anna Marina   +11 more
openaire   +3 more sources

Qualitative and quantitative evaluation of the BCR-ABL fusion gene in chronic myelogenous leukemia by flourescence in situ hybridization and molecular genetic methods.

Genetic Testing and Molecular Biomarkers, 2015
AIMS Fluorescence in situ hybridization (FISH) and quantitative real-time polymerase chain reaction (QRT-PCR) were used to diagnose or screen for minimal residual disease (MRD) in Philadelphia (Ph) chromosome-positive leukemia. We compared the diagnostic
S. Ozemri Sag, T. Yakut, O. Gorukmez, O. Gorukmez, M. Ture, M. Karkucak, T. Gulten, R. Ali   +7 more
semanticscholar   +1 more source

Closely Related BCR/ABL Oncogenes Are Associated with the Distinctive Clinical Biologies of Philadelphia Chromosome Positive Chronic Myelogenous and Acute Lymphocytic Leukemia

1988
The study of oncogene activation in naturally occurring human leukemias provides a useful approach to define the range of growth regulatory mechanisms used by hematopoietic stem cells. Recent analysis of the structural changes created by the Philadelphia chromosome translocation [t(9;22) — (q34;q11)] shows that two alternative regions of the BCR gene ...
openaire   +3 more sources

[Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008
To investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).By using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR).
Ya-zhen, Qin, Yan-rong, Liu, Jin-lan, Li, Hui, Wang, Yan, Chang, Jia-yu, Fu, Guo-rui, Ruan, Hui-lin, Shi, Jing-ying, Qiu, Dao-pei, Lu, Shan-shan, Chen   +10 more
openaire   +1 more source

Human medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/

Case Medical Research, 2019

semanticscholar   +1 more source

Extramedullary BCR-ABL positive T-lymphoblastic leukemia in a patient with chronic myelogenous leukemia

Community Oncology, 2012
JinMing Song, Mylene Go, Le Wang, Rene Rubin   +3 more
openaire   +2 more sources